Discovery & origin

• What Semax is and how an ACTH fragment became a brain peptide
• Why it upregulates BDNF and NGF without touching the cortisol axis
• How to weigh Russian clinical trials against Western RCT standards
• Where the evidence is solid, thin, or simply missing

1. 01 Discovery & origin From an ACTH fragment to a Russian brain peptide free
2. 02 Neuropeptide pharmacology Where Semax sits in the melanocortin family paid
3. 03 Chemistry & pharmacokinetics The structure, the half-life, and the puzzle in between paid
4. 04 Neurotrophic mechanisms The BDNF and NGF signature paid
5. 05 Neurochemistry How Semax tunes brain messengers paid
6. 06 Cognitive effects The nootropic claim, examined paid
7. 07 Neuroprotection & stroke The strongest clinical signal, and its limits paid
8. 08 Safety & side effects What we know, and the large gaps we do not paid
9. 09 Dosing & administration How Semax is prepared and given, for education only paid
10. 10 Regulatory landscape Approved in Russia, unapproved in the West paid
11. 11 Final exam & certification Pass the final exam to earn your specialist certificate. Exam

Semax grew out of decades of work on ACTH fragments. In the 1960s and 1970s, David de Wied in Utrecht showed that pieces of ACTH changed behavior and memory in animals without acting on the adrenal gland, separating the hormone’s brain effects from its stress-hormone job.

A Russian team at IMG RAS turned that idea into a drug, trimming ACTH to its active core and adding a protective tail. Russian regulators authorized it for medical use on 20 December 1994, but no sponsor ever ran the large Western trials needed for FDA or EMA approval.

Strip away the marketing and Semax is seven amino acids in a row. The first four, Met-Glu-His-Phe, are the active ACTH core; the last three, Pro-Gly-Pro, are a tail added to slow the enzymes that would otherwise chop the peptide apart in seconds.

That small change in design is the whole point. The bare ACTH core would be destroyed almost immediately, so the Pro-Gly-Pro tail buys it enough time to reach the brain after a nasal dose. Even the tail, once cleaved off, appears to do something on its own.

It helps to see Semax as a deliberate edit of a natural sequence. The body cleaves a large precursor into ACTH and related fragments; Semax keeps only positions 4 to 7 of that hormone and swaps the rest for the protective tail. That single edit captures the whole design philosophy: keep the part of the hormone that signals to the brain, discard the part that drives the adrenal gland, and armor what remains so it lasts long enough to act.

Before any mechanisms, here is the honest picture. The Semax evidence base is unusual: a deep, consistent body of animal mechanism work, a layer of small Russian clinical trials, and almost nothing that meets modern Western trial standards. That shape matters, because it is easy to mistake a tall stack of animal studies for clinical proof. The mechanism evidence is genuinely strong, the human evidence is genuinely thin, and most of both comes from a single Russian research lineage rather than independent labs worldwide.

Online, Semax is sold as a sharpening, focus-boosting nootropic. Held against the evidence, most of those claims are not flatly false, they are simply running far ahead of what has actually been tested in people.

Notice the pattern across the table. The mechanism claims are the best supported, the clinical claims are suggestive but soft, and the healthy-user claims that drive demand are the weakest. Reading each claim against its own evidence tier is the core skill this course builds.